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Safety and Preliminary Efﬁcacy of Vorinostat
With R-EPOCH in High-risk HIV-associated
Non-Hodgkin’s Lymphoma (AMC-075)
Juan C. Ramos,1 Joseph A. Sparano,2 Michelle A. Rudek,3 Page C. Moore,4
Ethel Cesarman,5 Erin G. Reid,6 David Henry,7 Lee Ratner,8 David Aboulaﬁa,9
Jeanette Y. Lee,4 Richard F. Ambinder,10 Ronald Mitsuyasu,11 Ariela Noy12
Abstract
We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide,
prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-
associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efﬁcacious with chemo-
therapy with complete response rate of 83% and 1-year event-free survival of 83%. VOR did not signiﬁcantly
alter chemotherapy steady-state concentrations, CD4D cell counts, or HIV viral loads.
Introduction: Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and
cytotoxic chemotherapy, induces viral lytic expression and cell killing in Epstein-Barr virus-positive (EBVþ) or human
herpesvirus-8-positive (HHV-8þ) tumors, and reactivates latent human immunodeﬁciency virus (HIV) for possible
eradication by combination antiretroviral therapy (cART). Patients and Methods:We performed a phase I trial of VOR
given with R-based infusional EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hy-
drochloride) (n ¼ 12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify
safe dosing and schedule. VOR (300 or 400 mg) was given orally on days 1 to 5 with each cycle of R-EPOCH for 10
high-risk patients with diffuse large B-cell lymphoma (1 EBVþ), 1 EBVþ/HHV-8þ primary effusion lymphoma, and 1
unclassiﬁable NHL. VOR was escalated from 300 to 400 mg using a standard 3 þ 3 design based on dose-limiting
toxicity observed in cycle 1 of R-EPOCH. Results: The recommended phase II dose of VOR was 300 mg, with
dose-limiting toxicity in 2 of 6 patients at 400 mg (grade 4 thrombocytopenia, grade 4 neutropenia), and 1 of 6 treated
at 300 mg (grade 4 sepsis from tooth abscess). Neither VOR, nor cART regimen, signiﬁcantly altered chemotherapy
steady-state concentrations. VOR chemotherapy did not negatively impact CD4þ cell counts or HIV viral loads, which
decreased or remained undetectable in most patients during treatment. The response rate in high-risk patients with
NHL treated with VOR(R)-EPOCH was 100% (complete 83% and partial 17%) with a 1-year event-free survival of 83%
(95% conﬁdence interval, 51.6%-97.9%). Conclusion: VOR combined with R-EPOCH was tolerable and seemingly
efﬁcacious in patients with aggressive HIV-NHL.
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Introduction
Individuals infected with human immunodeﬁciency virus
(HIV) are at an increased risk of developing highly aggressive non-
Hodgkin lymphoma (NHL). Recent studies have demonstrated
improved outcomes in patients with HIV-NHL approaching that
of the general population after the introduction of combination
antiretroviral therapy (cART) and newer chemotherapy para-
digms.1 A large retrospective pooled analysis describing the
outcome of patients with HIV-NHL in the contemporary cART
era reported 2-year survival rates of 67% for HIV-diffuse large B-
cell lymphoma (DLBCL), as compared with 24% in the pre-cART
era.2 Recent advancements in the treatment of HIV-DLBCL
might be attributed to the efﬁcacy of infusional regimens, such
as EPOCH (etoposide, prednisone, vincristine, cyclophospha-
mide, and doxorubicin), and the addition of rituximab (R) to
standard curative NHL regimens.3 R-EPOCH is the preferred
regimen for treating HIV-DLBCL and HIV-primary effusion
lymphoma (PEL) under current National Comprehensive Cancer
Network guidelines based on multiple phase II clinical trials and
retrospective studies.3 Despite these advancements, treatment of
HIV-NHL remains challenging in severely immune-compromised
patients and aggressive NHL variants that carry poorer prognosis,
such as plasmablastic lymphoma (PBL), PEL, and activated B-cell
(ABC) type DLBCL.4-7
Differences in clinical spectrum and biology of HIV-NHL might
be exploited therapeutically. For example, the high expression of
the multidrug resistance (MDR-1) gene might be overcome by
infusional regimens like EPOCH by prolonged continuous drug
exposure.8,9 Alternatively, despite their oncogenic potential, latent
gherpesviruses (Epstein-Barr virus [EBV] and human herpesvirus-
8 [HHV-8]) can be targeted therapeutically, as doxorubicin and
etoposide (EPOCH drugs), and histone deacetylase (HDAC) in-
hibitors disrupt viral latency.10-13 Moreover, in preclinical B-cell
lymphoma and hematologic malignancy models, the potent HDAC
inhibitor vorinostat (VOR) was highly synergistic with R, anthra-
cyclines, and etoposide.14-16 VOR given with R, cyclophosphamide,
etoposide, and prednisone was effective in elderly patients with
relapsed/refractory DLBCL.17 VOR induced HHV-8 lytic gene
expression and p53 acetylation leading to apoptosis and increased
survival in a PEL xenograft mouse model.18 VOR also re-activates
HIV, suggesting its potential role in eradicating latently infected
reservoirs in human hosts via HIV cytopathic effects and immune-
mediated mechanisms.19-21
Based on these concepts, the National Cancer Institute (NCI)-
funded AIDS Malignancy Consortium (AMC) performed a phase
I/II clinical trial (AMC-075) using VOR with R-EPOCH in
aggressive, non-Burkitt, HIV-NHL. The primary objectives were to
test the safety and the efﬁcacy of VOR when combined with
R-based chemotherapy and cART using complete response rate as
the primary study endpoint. We report the phase I portion here. To
evaluate toxicity, 2 VOR dose levels (300 mg or 400 mg given orally
on days 1 through 5 during each chemotherapy cycle) were tested
using a 3 þ 3 design. This enabled us to compare directly the
plasma steady-state concentrations of etoposide, doxorubicin, and
vincristine achieved at the 2 VOR dose levels during cART. This
trial is registered at http://clinicaltrials.gov as NCT01193842.
Patients and Methods
Eligibility Criteria
Twelve AMC sites in the United States enrolled patients after
written informed consent according to the Declaration of Helsinki.
Patients with HIV and absolute CD4þ count  50 cells/mm3, with
DLBCL or aggressive non-Burkitt NHL variants, were eligible.
Patients were untreated or had received a maximum of 1 cycle of
chemotherapy at time of enrollment.
Patients with any Ann Arbor stage (I-IV), age  18 years,
Eastern Cooperative Oncology Group (ECOG) performance status
(PS) 0-2, and adequate organ function were eligible. Non-
zidovudine based cART was required. For antiretroviral-naive
subjects at study entry, cART was started after cycle 1 to avoid
confounding side effects. Patients who had active hepatitis B virus
(surface antigen, core antigen, or viremia), or active hepatitis C
infection were ineligible. Patients who were only hepatitis B core
antibody-positive required prophylactic anti-hepatitis B virus ther-
apy. Patients with known central nervous system involvement by
lymphoma were ineligible.
Treatment Administration and Supportive Care
R was given at 375 mg/m2 intravenously (IV) for CD20þ lym-
phomas on day 1. R-EPOCH was given to patients with high-risk
NHL every 21 days for 6 cycles. Cyclophosphamide IV on day 5
was administered at initial dose of 375 mg/m2 when baseline CD4þ
count was 50 to 200 cells/mm3, or 750 mg/m2 if baseline CD4þ
count was > 200 cells/mm3. For subsequent cycles,
cyclophosphamide was dose-adjusted based on nadir counts
according to speciﬁed guidelines (see Supplemental Tables 1 and 2 in
the online version). Patients received VOR orally once on days 1 to 5.
Treatment and supportive care options are summarized in Table 1.
Clinical and Response Assessments
Response was assessed by standard whole body computerized
tomographic (CT) scan criteria22 after cycle 4, and posttreatment (4-8
weeks, and months 6, 12, 18, and 24). Positive emission tomographic
(PET) or CT-PET were required after the ﬁnal treatment cycle to
conﬁrm a complete response (CR). Subjects with bone marrow
involvement had a repeat biopsy to conﬁrm CR. Subjects with CR
after cycle 4 received up to 2 additional chemotherapy cycles (total, 6
cycles). Subjects who achieved only a partial response (PR) after cycle
4 had the option to continue at the discretion of the treating
physician. Subjects were followed every 3 months for 2 years post-
treatment, and then every 6 months for years 3 to 5.
Central Pathology Review, Immunohistochemistry, and
EBV-encoded Small RNA (EBER) in Situ Hybridization
Central pathology review was conducted at Weill Cornell Med-
ical College as previously described.23 Cases with adequate tissue
were categorized as germinal center (GC)-derived versus ABC
(noneGC)-type according to the tissue microarray classiﬁcation
algorithm published by Hans et al.24 Monoclonal antibodies to the
following antigens were used: CD10 (56C6; Leica Microsystems),
BCL-2 (124), BCL-6 (PG-B6p), MUM-1 (MUM1p) and Ki-67
(MIB-1) (DakoCytomation, Carpinteria, CA). EBV Probe ISH
Kit (Leica Microsystems, Wetzlar, Germany; Vision BioSystems
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Novocastra, Newcastle-upon-Tyne, UK) was used for in situ hy-
bridization for EBER. The cases were interpreted as positive for
CD10, BCL2, and MUM-1 when more than 30% of neoplastic
cells were immunoreactive, and BCL2 positivity was deﬁned
when  50% of cells had moderate to strong positivity. Nuclear Ki-
67 expression was determined semi-quantitatively as a percentage of
positive tumor cells. Cases were considered EBER-positive when a
hybridization signal was identiﬁed in the majority of neoplastic cells.
Correlative Studies
EBV expression was assessed by immunohistochemical detection
of LMP-1 or EBER by in-situ hybridization of diagnostic tumor
Table 2 Deﬁnition and Summary of DLT Events
DLT Deﬁnition
Hematologic toxicity  ANC <500/mm3 that did not improve to a level above 750/mm3 within 14 d
 Febrile neutropenia (ANC <1000/mm3) requiring hospitalization or IV antibiotics
 Platelet count <25/mm3 of any duration grade 4 anemia of any duration
Non-hematologic  Any toxicity causing a dose delay of >2 wk for the next treatment cycle
 Any adverse event  grade 3 except: fatigue, grade 2 alopecia, or grade 3 or 4
nausea, vomiting, and/or diarrhea that was responsive to treatment
 Grade 3 or 4 non-hematologic laboratory abnormalities that resolved to grade 1 or
baseline within 14 d
Vorinostat
Dose Level
Dosage and
Schedule
No. of Evaluable
Patients
No. of Patients With
Cycle 1 DLT Type of DLT
þ1 300 mg QD days 1-5 6 1 Grade 4 sepsis from tooth abscess
þ2 400 mg QD days 1-5 6 2 Grade 4 thrombocytopenia (n ¼ 2)
Abbreviations: ANC ¼ absolute neutrophil count; DLT ¼ dose-limiting toxicity; IV ¼ intravenously; QD ¼ daily.
Table 1 Treatment and Supportive Care
Drug or Treatment Dosing and Schedule
Vorinostat (VOR) PO on days 1-5 every 3 wk with rituximab-EPOCH
Dose level was assigned according to 3 þ 3 design: starting level þ1 (300 mg), level 1 (200 mg),
level þ2 (400 mg)
Rituximab (if CD20þ only) 375 mg/m2 IV on day 1 every 3 wk with chemotherapy (CHOP or EPOCH)
EPOCH Every 3 wk  6 cycles
Etoposide 50 mg/m2 IVCI on days 1-4  96 hr
Prednisone 60 mg/m2 PO on days 1-5
Doxorubicin 10 mg/m2 IVCI on days 1-4  96 hr
Vincristine 0.4 mg/m2 IVCI on days 1-4  96 hr
Cyclophosphamide (dose-adjusted) Starting dose: 375 mg/m2 if CD4 ¼ 50-200/mm3 with subsequent dose-adjustment, or
maximum dose of 750 mg/m2 if CD4 >200/mm3 IVPB on day 5
Supportive medications and treatment
G-CSF Started 24-48 hr after completion of chemotherapy
Pegﬁlgastrim 6 mg SC once
Or
Filgastrim 300 mg or 480 mg SC daily for 10 d or longer until ANC 1000/mm3
Infection prophylaxis Continuous
Trimethoprim-sulfamethoxazole (160-800 mg) 3 times weekly
or dapsone 100 mg PO daily
or atovoquone 1500 mg PO daily
Fluoroquinolone (anti-bacterial agent) No later than day 8 of chemotherapy until ANC 1000/mm3
Anti-herpetic agent (recommended)
CNS prophylaxis: intrathecal methotrexate or depocyte or
cytarabine (per drug package speciﬁcations)a
For a total of 4-6 doses
cART nonezidovudine-based regimen required Patients not on cART at study entry were required to start AFTER cycle 1 of chemotherapy
Abbreviations: ANC ¼ absolute neutrophil count; cART ¼ combination antiretroviral therapy; CHOP ¼ cyclophosphamide, doxorubicin, vincristine, and prednisolone; CNS ¼ central nervous system;
EPOCH ¼ etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; IV ¼ intravenously; IVCI ¼ intravenous continuous infusion; IVPB ¼ intravenous piggyback; PO ¼ orally; SC ¼
subcutaneously.
aCNS prophylaxis was required in patients who had lymphomatous involvement of bone marrow, testes, sinuses, or epidural regions.
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specimens at local and/or central pathology laboratories. T-cell
(CD4þ) subset analysis, and HIV viral load (VL) by quantitative
RNA polymerase chain reaction, were performed by local laboratories
at baseline, after cycle 2, and posttreatment (months 1, 6, and 12).
Pharmacokinetics (PK)
Serial plasma samples for PK analysis were collected at 24 to 48,
48 to 72, and 72 to 96 hours after the start of the ﬁrst chemo-
therapy infusion. Doxorubicin, etoposide, and vincristine concen-
trations were determined using a validated liquid chromatography-
tandem mass spectrometry method based on prior methods with
minor modiﬁcations.25-27 The clearance was determined by dividing
the drug-infusion rate by the steady-state concentrations, which was
the average of the 3 time points.
Deﬁnition of Dose-limiting Toxicity (DLT) and Adverse
Event (AE)
A DLT was deﬁned as an AE possibly, probably, or deﬁnitely
attributed to VOR-chemotherapy in the ﬁrst cycle (21 days) and
meeting criteria deﬁned in Table 2. Classiﬁcation of grade was
determined using the NCI Common Terminology Criteria for
Adverse Events, Version 4.0. For subsequent cycles, VOR doses
were modiﬁed according to the above-mentioned guidelines listed in
Supplemental Table 1 (in the online version).
Statistical Analyses
Patients were enrolled to establish the recommended phase II dose
(RPTD) of VOR using a standard 3 þ 3 design (Table 2). The study
planned to enroll between 9 and 18 participants during the dose
escalation phase, plus 3 additional participants in order to assure that
a total of 6 participants were treated at the recommended phase II
dose. After determining the RPTD, a phase II study was planned
with sample size of 90 participants equally divided between those
with and those without VOR, which would be sufﬁcient to detect the
difference between the CR rate proportions (ie, 70% for EPOCH
alone vs. 88% for VOR-EPOCH) with an odds ratio of 3.27 at the
one-sided 0.10 signiﬁcance level with power of 0.80 using the
Normal approximation for a 2-sample test of proportions. Summary
statistics were used to describe phase I patient baseline characteristics
listed in Table 3. Safety evaluation and tumor response evaluations
were tabulated by dose level. The tumor response rates with 95%
conﬁdence intervals were estimated for each dose group.
The effect of concurrent VOR and etoposide, doxorubicin, and
vincristine clearance as part of R-EPOCH was assessed. Summary
statistics were used to describe drug clearance by dose level. CYP3A4,
a cytochrome P450 enzyme, is involved in the metabolism of
doxorubicin (Pharm GKB https://www.pharmgkb.org/pathway/
PA165292177),28 etoposide (Pharm GKB https://www.pharmgkb.
org/pathway/PA2025),29 and vincristine (Pharm GKB https://www.
pharmgkb.org/pathway/PA150981002).30 In a post-hoc analysis,
patients were stratiﬁed into groups based on the known drug-drug
interaction potential via CYP3A4: concurrent CYP3A4 inhibitors,
concurrent CYP3A4 inducers, and no interaction potential or not on
cART. Correlations between drug clearance and VOR dose or
CYP3A4 interaction potential and between drug clearance and
toxicity were performed by Kruskal-Wallis analysis of variance by
ranks with post-hoc analysis using an all-pairs Tukey-Kramer test.
Mann-Whitney U tests were used to assess correlations between drug
exposure and toxicity. For each dose group, the Wilcoxon signed rank
test was used to evaluate the changes in HIV viral load and CD4þ
cell count from baseline to end of cycle 2, and 1, 6, and 12 months
after completion of chemotherapy.
Results
Patient Characteristics, Tumor Classiﬁcation, and
Associated Risk Features
Between December 2010 and November 2012, 14 patients were
enrolled. Eligible patients had at least 1 of the following high-risk
characteristics: age-adjusted international prognostic index (aa-IPI)
2-3, Ki-67  80%, post-GCB (also known as ABC) subtype
DLBCL, or any other aggressive non-GCB, non-Burkitt B-cell
NHL. Each of the following was considered an adverse factor for the
aa-IPI: stage III to IV, elevated serum lactate dehydrogenase, or
ECOG PS of 2.
Twelve patients of 14 patients enrolled were evaluable for treat-
ment response (Figure 1); 1 patient withdrew from the study during
cycle 1, and 1 patient with B-cell lymphoma, unclassiﬁable, with
features intermediate between DLBCL and Burkitt lymphoma (BL)
not otherwise speciﬁed was registered but not treated on protocol
after he was determined to be ineligible. The protocol was later
amended to include patients with B-cell lymphoma with features
intermediate between DLBCL and BL.
Patient characteristics, tumor classiﬁcation, and disease features
of 12 patients assessable for treatment response treated with VOR-
R-EPOCH are listed in Table 3. Ninety-two percent were male,
67% non-Hispanic white, 17% Hispanic, and 17% African
American. The median age was 48 years (range, 27-65 years). Two
(17%) patients were injection drug users. Ten (83%) patients were
on cART prior to enrollment; 2 patients began cART after cycle 1.
The median baseline absolute CD4þ count was 222 cells/mm3
(range, 91-754 cells/mm3), and < 100 cells/mm3 in 2 (17%) pa-
tients. Five (42%) patients had an undetectable HIV VL. Seven
(58%) had HIV viremia with a median VL of 22,400 copies/ml
(range, 25-482,000 copies/ml). Pathology was conﬁrmed in 9
available cases by stains performed at the central pathology labora-
tory. Two cases submitted did not yield enough diagnostic tissue,
and 1 case was not available; local institution pathology reports were
reviewed and diagnoses made accordingly. Ten cases were classiﬁed
as DLBCL (5 GC type, and 5 ABC type), 1 case as B-cell lym-
phoma, unclassiﬁable, with features of DLBCL and BL, and 1 case
as HHV-8þ/EBVþ PEL. One DLBCL case (ABC type) was EBVþ.
Ki-67 expression was  80% in 10 (91%) of 11 cases analyzed.
Nine (75%) patients had advanced stage lymphoma (III-IV by Ann
Arbor criteria), 9 (75%) had high baseline lactate dehydrogenase, 8
(67%) had high IPI risk, and 2 (17%) had an ECOG PS of 2.
Cycle I DLTs
One patient treated with R-EPOCH at VOR dose level 1 (300
mg) withdrew from the study early during cycle 1 of treatment, and
was not evaluable. One of 6 evaluable patients treated with
R-EPOCH at VOR 300-mg dose level experienced a DLT during
cycle 1 with grade 4 sepsis, arising from a tooth abscess; all 6
patients completed therapy. Two of 6 patients treated at the VOR
400-mg dose level had DLTs during cycle 1; both had grade 4
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thrombocytopenia with concurrent grade 4 neutropenia, and one of
them had bone marrow involvement. Grade 4 thrombocytopenia
did not occur at the 300-mg level. One patient with bone marrow
involvement treated at the 300-mg level did not experience signif-
icant neutropenia either. Grade 4 neutropenia also occurred in a
patient without bone marrow involvement at 300 mg after cycle 1,
and in another patient with limited stage disease at the 400-mg
level. The RPTD was 300 mg. At the VOR 400-mg dose, 5
patients completed treatment; 1 patient died of unrelated cause
(illicit drug overdose) before completing therapy. Other AEs for all
cycles are described in Table 4.
Treatment Efﬁcacy
The overall response rate in 12 evaluable patients with high-risk
NHL treated with VOR(R)-EPOCH was 100% (CR þ PR rates of
83% and 17%, respectively). The median follow-up time for the
survivors was 228 weeks (range, 34-278 weeks). To date, 3 patients
have died: one of illicit intravenous drug use after cycle 4 after
achieving a PR, and 2 CR patients after lymphoma relapse at
months 8 and 23 after starting treatment. The 1-year overall survival
(OS) and event-free survival (EFS) were both 83% (95% conﬁdence
interval [CI], 51.6%-97.9%) (Figure 2).
Treatment Effect on CD4þ Cell Count and HIV Viral
Load
Absolute CD4þ cell counts did not statistically differ from
baseline to end of cycle 2, 1 month, 6 months, and 12 months
posttreatment after VOR-chemotherapy (Table 5). During or after
VOR-R-EPOCH, the HIV VL became undetectable in 4 patients,
remained undetectable in 2 patients, and decreased initially in 1
patient before exacerbating after cycle 6 (300 mg VOR level).
Transient “blips” in HIV viremia, characterized by detectable levels,
occurred once either during VOR-chemotherapy or post-treatment
in 5 patients: 3 patients after 2 cycles, and 2 patients 1-month
posttreatment.
PKs
PK data were available on 11 patients treated with VOR(R)-
EPOCH. Doxorubicin (P ¼ .93 for VOR; P ¼ .55 for cART), eto-
poside (P¼ .65 for VOR; P¼ .89 for cART), and vincristine (P¼ .52
for VOR; P ¼ .76 for cART) clearance were similar regardless of the
Table 3 Baseline Demographics and Characteristics of
Evaluable Patients With High-risk NHL
Characteristic N Value %
Gender
Female 1 8
Male 11 92
Race/ethnicity
White/non-Hispanic 8 67
White/Hispanic 2 17
African American 2 17
Age, y
Median (range) 48 (27-65)
CDC risk group
Homosexual/bisexual contact 10 83
Heterosexual contact 3 25
Multiple risks
Homosexual/bisexual þ
heterosexual contact
8
Homosexual/bisexual contact þ IV
drug use
2 17
Absolute CD4 count, cells/mm3
Median (range) 222 (91-754)
HIV viral load, copies/ml
Undetectable or below institutional
limit
5 42
Positive 7 58
Median (range) 22,400
(25-482,000)
Ann Arbor stage
I-II 3 25
III-IV 9 75
ECOG PS
0-1 10 83
2 2 17
aa-IPI risk
0-1 4 33
2-3 8 67
LDH elevation
Yes 9 75
No 3 25
Pathologic diagnosis
DLBCL
GC type 5 42
ABC type 5 42
Other 2 17
B-cell lymphoma, unclassiﬁable,
with features between DLBCL
and BL
1 8
PEL-extracavitary or solid variant 1 8
Ki-67 expression (n ¼ 11 available)
80% 10 91
<80% 1 9
Table 3 Continued
Characteristic N Value %
EBV expression
Positive 2 (1 HHV-
8þ)
17
Negative 10 83
Abbreviations: aa-IPI ¼ age-adjusted International Prognostic Index; ABC ¼ activated B-cell;
BL ¼ Burkitt lymphoma; CDC ¼ Center for Disease Control and Prevention; DLBCL ¼ diffuse
large B-cell lymphoma; EBV ¼ Epstein Barr virus; ECOG PS ¼ Eastern Cooperative Oncology
Group performance status; GC ¼ germinal center; HIV ¼ human immunodeﬁciency virus;
IV ¼ intravenous; LDH ¼ lactose dehydrogenase; NHL ¼ non-Hodgkin lymphoma;
PEL ¼ primary effusion lymphoma.
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dose of VOR or cART regimen (see Supplemental Table 3 in the
online version). In addition, doxorubicin, etoposide, and vincristine
clearances were not associated with any AEs (P > .05).
Discussion
Although the clinical outcome of patients with HIV-NHL has
improved since the advent of cART, management remains chal-
lenging in those with high IPI score, ABC type DLBCL, “double
hit” DLBCL, PEL, and PBL. The phase I component of this phase I
to II trial was designed to determine the appropriate dose of VOR to
combine with R-EPOCH for a randomized phase II study of R-
EPOCH with or without VOR in HIV-associated B-cell lymphoma
(available at http://clinicaltrials.gov as NCT01193842). In the
phase I study, VOR with R-EPOCH was generally well-tolerated
and safe at the RPTD. The main reason for using VOR for only
5 days was to ensure safety in this vulnerable and previously un-
tested HIV population. The 5-day exposure was based on existing
toxicity data at the time from ongoing clinical studies combining
VOR with chemotherapy at higher doses or given for a longer
period.17,31 One of these trials was a phase I/II study testing
VOR þ combination chemotherapy (cyclophosphamide, etoposide,
prednisone, and rituximab) in elderly patients with refractory
DLBCL.17 In this trial, VOR dose escalation began at 300 mg and
increased up to 400 mg daily for 10 days during each 28-day
chemotherapy cycle. The MTD for VOR was 300 mg.17 In
another phase I/II trial, VOR 400 mg daily on days 1 to 9 com-
bined with R-CHOP (cyclophosphamide, doxorubicin, vincristine,
and prednisolone). for DLBCL (SWOG S0806 trial) resulted in
excess rates of febrile neutropenia and sepsis, leading to a reduction
in the duration of VOR to days 1 to 5 for the remainder phase II
study.31 In AMC-075, we elected to combine VOR on days 1 to 5
with EPOCH (a 5-day regimen) because VOR was known to
synergize with rituximab, anthracyclines, and etoposide.14-16 In
addition, because in AMC-034 the rate of grade 3 or 4 neutropenia
was 43% in patients who received R-EPOCH, with febrile neu-
tropenia occurring in 16%, we did not want to compromise a
potentially curative therapy using excessive doses of VOR. In this
small study, neither VOR nor cART regimen signiﬁcantly altered
chemotherapy steady-state concentrations. The AMC-075 phase II
study recently closed to accruals, and the results will be reported
after completion of minimum time for patient follow-up and data
analysis.
The preliminary results from AMC-075 phase I trial suggest
promising antitumor activity in this high-risk population with HIV
and aggressive B-cell NHL subtypes. The CR rate in 12 patients was
83% with 1-year EFS of 83% (95% CI, 51.6%-97.9%). In our
previous trial (AMC 034), the 1-year progression-free survival (PFS)
in the concurrent R-EPOCH arm was 78% (95% CI, 67%-90%),
which compared favorably over PFS observed with R-CHOP (48%;
95%CI, 32%-64%) in the AMC 010 trial, suggesting that infusional
EPOCH contributed to a better outcome.3,32 A phase II study per-
formed at the NCI using short-course EPOCH with dose-dense rit-
uximab (SC-EPOCH-RR) for newly diagnosed HIV-DLBCL with
suspension of cART during therapy demonstrated 5-year PFS andOS
of 84% and 68%, respectively, but outcomes were markedly inferior
in the non-GCB subtype with 5-year PFS of 44%.33 The AMC-075
phase I study reported here included 12 patients with high-risk NHL
features: 5 patients with ABC-type DLBCL, 5 patients with GCB-
type who had high age-adjusted IPI scores or tumors with a high
Ki-67 proliferative index ( 80%), 1 patient with unclassiﬁable fea-
tures between DLBCL and BL, and 1 patient with extracavitary PEL
variant. The high CR and 1-year EFS rates are encouraging in this
setting. In SWOG S0806, which combined VOR with R-CHOP for
DLBCL in the non-HIV setting, theOR rate with was 81% (95%CI,
69%-90%) with an estimated 2-year PFS of 72% (95% CI, 58%-
81%), which was slightly more than 68% expected from R-CHOP
alone per IPI adjusted historical rate, but less than an IPI-adjusted
target of 78%; consequently, the investigators concluded that such
results were not sufﬁcient to warrant further investigation of VOR
plus R-CHOP in DLBCL.31
We studied VOR in combination with standard chemotherapy in
order to augment the anti-tumor effects of chemotherapy, and to
target latently infected HIV-harboring reservoirs and g-herpesvi-
ruses (EBV and HHV-8) in positive tumors, which occur at a
signiﬁcantly higher frequency in the setting of HIV infection as
compared with the general population.34 HDAC inhibitors alter
chromatin state via acetylation of lysine residues in histones, thus
Figure 1 Consortium Diagram. *Histologic DLBCL Subtypes:
Deﬁned as Either GCB or ABC (Also Known as Post-
GCB). By Immunophenotypic Criteria (GCB Type Was
Considered When CD10 Was Expressed in > 30% of
Cells, or if CD10L, BCL6D, and IRF4/MUM1L; All
Others Were Considered to be ABC Type or Non-GC)
Aggressive HIV-Related B-cell Non-Hodgkin’s Lymphoma
HIGH-RISK GROUP
n=14
Aa-IPI 2-3 or Ki-67 ≥80% or ABC DLBCL or 
any other aggressive non-Burkitt types*
Rituximab-EPOCH + vorinostat
Dose Level Vorinostat Dose
-1 200 mg QD days 1-5
+1 300 mg QD days 1-5
+2 400 mg QD days 1-5
Enrolled
(n=14)
Allocation
Follow up
Analysis
Completed treatment (n=11)
Did not complete treatment (n=1)
-Non-treatment related death
Early Withdrawal (n=2)
-Patient decision (n=1)
-Determined ineligible (n=1)
Analyzed for response (n=12)
Vorinostat MTD determined 
at 300 mg
Abbreviations: aa-IPI ¼ age-adjusted International Prognostic Index; ABC ¼ activated Becell-
like; DLBCL ¼ diffuse large B-cell lymphoma; EPOCH ¼ etoposide, prednisone, vincristine,
cyclophosphamide, and doxorubicin; GCB germinal center Becell-like; MTD ¼ maximum
tolerated dosage; QD ¼ daily.
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facilitating the expression of silenced cellular and viral genes.
Acetylation of BCL6, which is a proto-oncogene frequently over-
expressed in DLBCL, inhibits its function. In the Em-myc B-cell
lymphoma mouse model, VOR selectively killed Em-myc
lymphoma cells mediated by pro-apoptotic proteins Bid and Bim.35
In our study, 2 (17%) patients had geherpesvirus-associated NHL;
1 patient had EBVþ DLBCL, and 1 had EBVþ HHV-8þ solid PEL
variant. The patient with PEL had a sustained CR. The patient with
Table 4 Treatment-related Adverse Events at the Patient Level
Dose Level
All Cycles
VOR(R)-EPOCH (300 mg) (n [ 6) VOR(R)-EPOCH (400 mg) (n [ 6)
Toxicities/Grade Grade £2 Grade ‡3 Grade £2 Grade ‡3
Hematologic
Anemia 2 1 1 3
Febrile neutropenia n/a 2 n/a 2
Lymphopenia 0 1 1 2
Neutropenia 1 3 0 4
Thrombocytopenia 2 2 1 3
Non-hematologic
Alopecia 0 0 0 0
Bone pain 0 0 0 0
Cardiac 1 1 0 1
Death-NOS n/a 1 n/a 0
Dermatologic 3 0 2 0
Dyspnea 0 0 0 0
Eye disorders 1 0 0 0
Fatigue 0 0 0 0
Gastrointestinal
Abdominal pain 1 1 1 0
Anal mucositis 0 0 1 0
Colitis 0 1 0 0
Constipation 3 0 2 0
Diarrhea 1 2 1 0
Dyspepsia 1 0 0 0
Esophagitis 1 0 1 0
Intra-abdominal
hemorrhage
0 1 0 0
Muscositis oral 1 0 2 0
Nausea 5 0 1 0
Vomiting 1 1 1 0
Generalized symptoms 4 0 5 1
Hepatic 1 1 1 1
Infection 2 4 2 0
Infusion reaction 1 0 0 0
Metabolic 4 1 5 1
Musculoskeletal 4 0 1 0
Neurologic 5 0 3 0
Oligospermia 0 0 0 0
Paresthesia 0 0 0 0
Procedural complication 0 1 0 0
Psychiatric 1 0 1 0
Respiratory, thoracic, and
mediastinal
4 0 0 0
Vascular 3 0 0 0
Abbreviations: NOS ¼ not otherwise speciﬁed; R ¼ rituximab; VOR ¼ vorinostat.
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EBVþ ABC-type DLBCL had a PR after 4 cycles, but was lost to
follow-up. Although the number of patients in this study was too
small to draw any conclusions about the effectiveness of
VOR-containing regimen over standard chemotherapy in
geherpesvirus-associated NHLs, our recently completed random-
ized phase 2 study (VOR[R]-EPOCH vs. R-EPOCH alone)
included a total of 90 patients with DLBCL and other
geherpesvirus-associated lymphomas, including PBL and PEL, and
may provide further insights in the near future.
VOR was a logical drug choice for HIV-NHL as it induces HIV
transcription in latently infected CD4þ cells.19-21 The term “shock
and kill” refers to activating viral transcription leading to viral
cytopathic effects and immune-mediated cell death.36 In our study,
reduction of HIV VL occurred during treatment in several patients
already on cART who had viremia at baseline, but there was no
negative overall impact on CD4þ cell counts. Subjects who had
HIV VL below detection at baseline generally continued to have
suppressed virus, but transient “blips” were observed in some
patients. These ﬁnding were surprising because the opposite effect
(early increase in viremia) was expected with VOR-chemotherapy.
In recent clinical studies, VOR disrupted HIV provirus latency
in vivo, and induced a transient increase in cell-associated HIV
Figure 2 Survival for the Study Population. A, One-year Event-free Survival for the Entire Study Population (n [ 12). B, One-year
Overall Survival for the Entire Study Population (n [ 12)
Juan C. Ramos et al
Clinical Lymphoma, Myeloma & Leukemia March 2018 - 187
Table 5 Absolute CD4 Counts and HIV Viral Loads From Collected Samples of Study Patients at Baseline, During VOR Chemotherapy,
and After Completion of Treatment
Patient ID/
Laboratory Test Current ART
VOR Dose
Level, mg Baseline After Cycle 2
Posttreatment
1 mo 6 mo 12 mo
075-061-001 RTV, DRV, FTC, TDF 300
Absolute CD4 count,
cells/ml
178 321 234 359 e
HIV VL, copies/ml 282,977 92 54 UD (<48) e
075-041-002 EFV, FTC, TDF 300
Absolute CD4 count,
cells/ml
426 384 394 e e
HIV VL, copies/ml UD (<20) UD (<20) UD (<20) e e
075-061-003 Started after cycle 1 300
Absolute CD4 count,
cells/ml
258 458 212 334 e
HIV VL, copies/ml 55,116 764 UD (<48) UD (<48) e
075-031-013 FTC, ETR, TDF 300
Absolute CD4 count,
cells/ml
91 100 38 e e
HIV VL, copies/ml 22,400 322 235,000 e e
075-150-014 FTC, NVP, TDF 300
Absolute CD4 count,
cells/ml
754 810 445 e e
HIV VL, copies/ml 9034 2076 UD (<40) e e
075-120-016 3TC, EFV, FTC, TDF 300
Absolute CD4 count,
cells/ml
279 407 338 354 448
HIV VL, copies/ml UD (<20) 30 UD (<20) UD (<75) UD (<20)
075-041-004 FTC, ETR, RAL 400
Absolute CD4 count,
cells/ml
134 183 227 341 284
HIV VL, copies/ml UD (<48) 46 UD (<20) UD (<20) UD (<20)
075-080-006 ABC, 3TC, NVP 400
Absolute CD4 count,
cells/ml
269 282 237 314 373
HIV VL, copies/ml UD (<20) UD (<20) 549 UD (<20) 548
075-060-007 Started after cycle 1 400
Absolute CD4 count,
cells/ml
186 125 137 157 150
HIV VL, copies/ml 482,000 1000 UD (<48) UD (<48) UD (<20)
075-152-009 EFV, FTC, TDF 400
Absolute CD4 count,
cells/ml
485 412 218 357 350
HIV VL, copies/ml UD (<40) UD (<40) 49 UD (<40) UD (<40)
075-080-011 RTV, DRV, RAL 400
Absolute CD4 count,
cells/ml
96 64 136 126 126
HIV VL, copies/ml 88 22 23 2419 4377
075-041-012 RTV, MVC, RAL 400
Absolute CD4 count,
cells/ml
109 221 e e e
HIV VL, copies/ml 25 UD (<20) e e e
Abbreviations: ABC ¼ abacavir; ART ¼ antiretroviral therapy; DRV ¼ darunavir; EFV ¼ efavirenz; ETR ¼ etravirine; FTC ¼ emtricitabine; LPV ¼ lopinavir; MVC ¼ maraviroc; NPV ¼ nevirapine;
RAL ¼ raltegravir; RTV ¼ ritonavir; 3TC ¼ lamivudine; TDF ¼ tenofovir; UD ¼ undetectable; VL ¼ viral load; VOR ¼ vorinostat.
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RNA in several patients receiving suppressive cART, followed by
reduction during the ﬁrst few days of treatment.37,38 In our study, it
is possible that a transient increase of HIV viremia may have
occurred early in patients; however, the ﬁrst VL after starting
treatment was measured after 2 chemotherapy cycles (> 26 days
later). Alternatively, our ﬁndings suggest either a possible shutdown
of HIV transcription early after VOR-chemotherapy, or reduction
of HIV harboring reservoirs from cytotoxic effects induced by
VOR-chemotherapy, although mathematical models so far suggest
VOR treatment does not induce latently infected cell killing.39
Preliminarily, analysis of latent HIV reservoirs before and after
completion of treatment using quantitative viral outgrowth assay in
1 patient revealed no signiﬁcant impact of VOR-chemotherapy
(personal communication); additional latent HIV reservoirs
studies are underway in patients of the phase II study.
In summary, combining VOR with R-EPOCH and cART is safe
in aggressive HIV-associated NHLs. The impact of VOR given
concomitantly with R plus cytotoxic chemotherapy on treatment
efﬁcacy, HIV VL, and infected reservoirs will be more deﬁnitively
addressed in our recently enrolled randomized phase II trial. Future
directions include the addition of newer targeted agents in speciﬁc
NHL subsets.
Clinical Practice Points
 Our group previously investigated infusional EPOCH in com-
bination with concurrent or sequential R for aggressive B-cell
HIV-NHL (AMC-034), demonstrating a 78% 1-year PFS with
concurrent R-EPOCH, which compared favorably over R-
CHOP (48% 1-year PFS) in AMC-010.
 Another NCI phase II study using short-course EPOCH with
dose-dense R for newly diagnosed HIV-DLBCL demonstrated a
5-year PFS of 84%, but only 48% in non-GCB DLBCL.
 Therefore, treatment of HIV-NHL remains challenging in non-
GCB DLBCL, and other aggressive and often viral-associated
NHL variants.
 We performed a phase I trial (AMC-075) of VOR, a histone
deacetylase inhibitor that enhances anti-tumor chemotherapy
and R effects, induces viral lytic expression in EBVþ or HHV-8þ
tumors, and reactivates latent HIV for possible eradication of
infected cell reservoirs, in combination with R-EPOCH on days
1-5 and cART in aggressive HIV-NHL.
 Twelve patients (5 ABC-DLBCL [1 EBVþ], 5 GCB-DLBCL
with high age-adjusted IPI scores or Ki-67  80%, 1 unclassi-
ﬁable with features between DLBCL and Burkitt lymphoma,
and 1 EBVþ/HHV-8þ primary effusion lymphoma) were
evaluated.
 VOR was tolerable and safe at 300 mg with CR rate and 1-year
PFS of 83%, and did not signiﬁcantly alter chemotherapy steady-
state concentrations, CD4þ cell counts, or HIV viral loads.
 The clinical impact of adding VOR to R-chemotherapy for the
treatment of HIV-NHL will be more deﬁnitively addressed in
our recently enrolled randomized phase II trial.
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Supplemental Table 1 Dose Modiﬁcations for Cytopenias
Event Action
ANC nadir on any cycle <500/mm3 on 2 nonconsecutive
days at least 3 d apart and/or platelets <25,000/mm3 in
the previous cycle
1. For subjects on vorinostat:
 Reduce vorinostat by 100 mg daily (to a minimum of 200 mg daily). Give chemotherapy
at dose in previous cycle (do not escalate cyclophosphamide).
 If event recurs after vorinostat dose reduction, reduce vorinostat again by 100 mg daily
(to a minimum of 200 mg daily). Give chemotherapy at dose in previous cycle
(do not escalate cyclophosphamide during vorinostat dose reduction).
 If event recurs after a minimum vorinostat dose of 200 mg, discontinue vorinostat
permanently.
 If event recurs again after no vorinostat, reduce cyclophosphamide by 187 mg/m2.
2. If subject has never received vorinostat, reduce cyclophosphamide by 187 mg/m2.
ANC <500/mm3  3 d or platelets <25,000/mm3  3 d,
AND subject is receiving no cyclophosphamide or vorinostat in the
previous cycle
Reduce doxorubicin and etoposide by 25% of the full dose.
ANC nadir 500/mm3 AND platelet nadir 50,000/mm3 in the
previous cycle
Increase cyclophosphamide dose by 187 mg/m2 each cycle to maximum dose of 750 mg/m2.
Abbreviation: ANC ¼ absolute neutrophil count.
Supplemental Table 2 EPOCH Dose Modiﬁcation for Day 1 Counts After a 2-Week Delay
Platelets
ANC (2-wk Delay)
‡1000/mm3 750-999/mm3 <750/mm3
75,000/mm3 Full-dose Reduce cyclophosphamide by 187 mg/m2.
Do not administer cyclophosphamide if
previous dose was 187 mg/m2.
If the participant received no cyclophosphamide
in the previous cycle, reduce doxorubicin and
etoposide by 25% of previous dose.
Hold treatment
and remove participant from study
50,000-75,000/mm3 Reduce cyclophosphamide by 187 mg/m2.
Do not administer cyclophosphamide if
previous dose was 187 mg/m2.
If the participant received no cyclophosphamide
in the previous cycle, reduce doxorubicin and
etoposide by 25% of previous dose.
Hold treatment and remove participant
from study
<50,000/mm3 Hold treatment and remove participant from study.
If ANC  750/mm3 but < 1000/mm3, or platelets  50,000/mm3 but < 75,000/mm3 after 2-week delay, participant could be treated only after dose modiﬁcations per table above.
Abbreviations: ANC ¼ absolute neutrophil count; EPOCH ¼ etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.
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Supplemental Table 3 Doxorubicin, Etoposide, and Vincristine Clearance in the Presence or Absence of cART
n Doxorubicin (L/hr) Etoposide (L/hr) Vincristine (L/hr)
Vorinostat doses
1500 mg 6 78.6  48.0 3.0  1.6 22.4  10.2
2000 mg 5 76.0  47.9 2.4  0.7 16.8  8.9
cART-containing regimen
None or noninteracting 6 77.7  45.2 3.0  1.5 17.9  11.8
CYP3A4 inducer 3 97.2  49.0 2.5  0.7 21.9  9.1
CYP3A4 inhibitor 2 10.6, 83.1 1.6, 2.8 20.1, 25.3
Overall 11 77.4  45.5 2.7  1.2 19.9  9.6
Abbreviation: cART ¼ combination antiretroviral therapy.
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